These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33850766)

  • 1. Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study.
    Chen J; Ye W; Jiang W; Li X; Liu R; Lin B; Xiang J; Tian W; Bai J; Zuo T; Lin B; Guo Y; Zheng S
    Transl Androl Urol; 2021 Mar; 10(3):1321-1331. PubMed ID: 33850766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients.
    Anwaier A; Chen J; Zhou H; Zhao X; Zheng S; Li X; Qu Y; Shi G; Zhang H; Wu J; Ye D
    Transl Androl Urol; 2022 May; 11(5):694-709. PubMed ID: 35693709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
    Pérez-Valderrama B; Arranz Arija JA; Rodríguez Sánchez A; Pinto Marín A; Borrega García P; Castellano Gaunas DE; Rubio Romero G; Maximiano Alonso C; Villa Guzmán JC; Puertas Álvarez JL; Chirivella González I; Méndez Vidal MJ; Juan Fita MJ; León-Mateos L; Lázaro Quintela M; García Domínguez R; Jurado García JM; Vélez de Mendizábal E; Lambea Sorrosal JJ; García Carbonero I; González del Alba A; Suárez Rodríguez C; Jiménez Gallego P; Meana García JA; García Marrero RD; Gajate Borau P; Santander Lobera C; Molins Palau C; López Brea M; Fernández Parra EM; Reig Torras O; Basterretxea Badiola L; Vázquez Estévez S; González Larriba JL
    Ann Oncol; 2016 Apr; 27(4):706-11. PubMed ID: 26658889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.
    Sheng X; Jin J; He Z; Huang Y; Zhou A; Wang J; Ren X; Ye D; Zhang X; Qin S; Zhou F; Wang B; Guo J
    BMC Cancer; 2020 Mar; 20(1):219. PubMed ID: 32171288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
    Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
    Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Center.
    Wang B; Song JW; Chen HQ
    Front Pharmacol; 2020; 11():517672. PubMed ID: 33192500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
    Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
    Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
    Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
    Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
    Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
    Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
    BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.
    Procopio G; Bamias A; Schmidinger M; Hawkins R; Sánchez AR; Estevez SV; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Rodriguez CS; Jonasch E
    Clin Genitourin Cancer; 2019 Jun; 17(3):e526-e533. PubMed ID: 31196680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
    Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale".
    Cecere SC; Rossetti S; Cavaliere C; Della Pepa C; Di Napoli M; Crispo A; Iovane G; Piscitelli R; Sorrentino D; Ciliberto G; Maiolino P; Muto P; Perdonà S; Berretta M; Pignata S; Facchini G; D'Aniello C
    Front Pharmacol; 2016; 7():287. PubMed ID: 27630568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
    Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
    Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting.
    Nikic P; Babovic N; Dzamic Z; Salma S; Stojanovic V; Matkovic S; Pejcic Z; Juskic K; Soldatovic I
    Front Oncol; 2022; 12():892156. PubMed ID: 35756652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
    Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
    Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.
    Sella A; Michaelson MD; Matczak E; Simantov R; Lin X; Figlin RA
    Clin Genitourin Cancer; 2017 Apr; 15(2):291-299.e1. PubMed ID: 27638198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.